MegaPro Biomedical Co., Ltd.
🇹🇼Taiwan
Clinical Trials
6
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaLymph Node Metastasis
- Interventions
- Drug: MPB-2043 of 2.0 mg/kgDrug: MPB-2043 of 0.5 mg/kgDrug: MPB-2043 of 3.0 mg/kgDrug: MPB-2043 of 1.0 mg/kg
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06540443
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04643418
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia
Phase 2
Terminated
- Conditions
- Iron Deficiency Anemia
- Interventions
- Drug: IOP Injection / MPB-1514
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT03485053
- Locations
- 🇺🇸
North America Research Institute, Azusa, California, United States
🇺🇸Valley Renal Medical Group, Northridge, California, United States
🇺🇸Whittier Internal Medicine and Nephrology Medical Group, Whittier, California, United States
The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Drug: IOP Injection (MPB-1523)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT03407495
- Locations
- 🇨🇳
Chang Gung Medical Foundation, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects
Phase 1
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Drug: IOP Injection
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- MegaPro Biomedical Co. Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03399214
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei county, Taiwan
- Prev
- 1
- 2
- Next
News
No news found